ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

McMurray, John J. V.*; Wheeler, David C.; Stefansson, Bergur V.; Jongs, Niels; Postmus, Douwe; Correa-Rotter, Ricardo; Chertow, Glenn M.; Greene, Tom; Held, Claes; Hou, Fan-Fan; Mann, Johannes F. E.; Rossing, Peter; Sjostrom, C. David; Toto, Roberto D.; Langkilde, Anna Maria; Heerspink, Hiddo J. L.南方医科大学
Circulation2021-2-2DOI: 10.1161/CIRCULATIONAHA.120.051675
72被引24阅读
引用收藏
分享

摘要

BACKGROUND: Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in these patients and the effect of dapagliflozin on either type of event, taking account of history of cardiovascular disease. @@@ METHODS: In the DAPA-CKD trial (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease), 4304 participants with chronic kidney disease were randomly assigned to dapagliflozin 10 mg once daily or placebo. The primary end point was a composite of sustained decline in estimated glomerular filtration rate >= 50%, end-stage kidney disease, or kidney or cardiovascular death. The secondary end points were a kidney composite outcome (primary end point, minus cardiovascular death), the composite of hospitalization for heart failure or cardiovascular death, and all-cause death. In a prespecified subgroup analysis, we divided patients into primary and secondary prevention subgroups according to history of cardiovascular disease. @@@ RESULTS: Secondary prevention patients (n=1610; 37.4%) were older, were more often male, had a higher blood pressure and body mass index, and were more likely to have diabetes. Mean estimated glomerular filtration rate and median urinary albumin-to-creatinine ratio were similar in the primary and secondary prevention groups. The rates of adverse cardiovascular outcomes were higher in the secondary prevention group, but kidney failure occurred at the same rate in the primary and secondary prevention groups. Dapagliflozin reduced the risk of the primary composite outcome to a similar extent in both the primary (hazard ratio, 0.61 [95% CI, 0.48-0.78]) and secondary (0.61 [0.47-0.79]) prevention groups (P-interaction=0.90). This was also true for the composite of heart failure hospitalization or cardiovascular death (0.67 [0.40-1.13] versus 0.70 [0.52-0.94], respectively; P-interaction=0.88), and all-cause mortality (0.63 [0.41-0.98] versus 0.70 [0.51-0.95], respectively; P-interaction=0.71). Rates of adverse events were low overall and did not differ between patients with and without cardiovascular disease. @@@ CONCLUSIONS: Dapagliflozin reduced the risk of kidney failure, death from cardiovascular causes or hospitalization for heart failure, and prolonged survival in people with chronic kidney disease, with or without type 2 diabetes, independently of the presence of concomitant cardiovascular disease.

学科与关键词

关键词
cardiovascular diseasesheart failurerenal insufficiencychronicsodium-glucose transporter 2 inhibitors
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Circulation
发表日期
2021-02-02
卷期
第 143 卷, 第 5 期
页码
438-448
DOI
10.1161/CIRCULATIONAHA.120.051675
语言
ENGLISH
期刊收录
NSL
期刊等级
1区
成果收录
SCIE
资助标注
AstraZeneca; British Heart Foundation Center of Research Excellence [RE/18/6/34217]

作者

  • M

    McMurray, John J. V. (通讯) (第一作者)

  • W

    Wheeler, David C.

查看全部 16 位作者收起作者
  • S

    Stefansson, Bergur V.

  • J

    Jongs, Niels

  • P

    Postmus, Douwe

  • C

    Correa-Rotter, Ricardo

  • C

    Chertow, Glenn M.

  • G

    Greene, Tom

  • H

    Held, Claes

  • H

    Hou, Fan-Fan

    southern med univ

  • M

    Mann, Johannes F. E.

  • R

    Rossing, Peter

  • S

    Sjostrom, C. David

  • T

    Toto, Roberto D.

  • L

    Langkilde, Anna Maria

  • H

    Heerspink, Hiddo J. L.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417